BioSpace News Archive

HCP, Inc. (NYSE: HCP) announced today that it has closed an amended and restated credit agreement providing for a $2.5 billion unsecured revolving credit facility and a new $250 million unsecured term loan facility (collectively, the “Credit Facilities”).

Therapix Biosciences Ltd. (“Therapix” or the “Company”) (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market

CIOs must be positioned as true thought partners with executive leadership

NeurologyLive®, a digital and print multimedia platform dedicated to providing health care professionals treating neurological diseases with direct access to expert-driven, practice-changing news and insights in neurology, presents its most recent “Peer Exchange” panel discussion, “Understanding Hereditary ATTR (hATTR) Amyloidosis and the Recent Advances in Management.

A trend is developing: gamers and live content creators are using their platforms to make a positive impact on other people.

Essity, the global hygiene and health company, is holding its Investor Day in Stockholm, Sweden.

BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel CELL+GENE™ platform to develop regenerative medicines for intractable diseases, announced that the company will present at the following upcoming conferences.

Cadent Therapeutics announced the receipt of the second milestone payment from Novartis following the initiation of a Phase 2 clinical study of MIJ821, a subtype selective NMDA receptor negative allosteric modulator, in development for treatment-resistant depression.

Acorda Therapeutics, Inc. announced that Ron Cohen, M.D., Acorda’s President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.

Hospital for Special Surgery (HSS), the world’s largest academic medical center focused on musculoskeletal health, today announced that Andrew D. Pearle, MD, will succeed Bryan T. Kelly, MD, as chief of the HSS Sports Medicine Institute.